-
Achieved 22% total revenue growth in Q4 2025, driven by a 31% increase in clinical revenue as the core business accelerated toward historic levels.
-
Nearly 1 petabyte of genomic data will be processed by 2025, doubling the volume two years ago due to a market shift toward large composite panels and multi-omic analysis.
-
Adjusted gross margin expanded by 140 basis points to 74.2% through a major architectural upgrade that increased computing capacity tenfold and reduced total genome analysis time to less than 6 hours.
-
Save two large integrated health systems in the United States, representing a combined potential of 60,000 annual genomic tests and 1 million oncology/rare disease patients.
-
Maintaining high platform stickiness with below 1% annual revenue and a Net Promoter Score of 67, validating the decentralized AI implementation model.
-
Announced a leadership transition with Ross McCain to become CEO in July 2026, while founder Jorgi Kimblong moves to CEO to focus on technological innovation.
-
Leveraged diverse data streams from 75 countries to launch Digital Twins for Lung Cancer, enabling AI-powered virtual simulations for treatment selection.
-
Estimated 2026 revenue between $92 million and $94 million, with growth roughly half weighted to 2025 record booking transaction usage as a 2025 record.
-
Management anticipates net positive biopharma shares in 2026 as their story begins to resonate with senior members of the top 20 pharmaceutical companies, although they are not yet predicting dramatic acceleration or ‘hockey stick’ growth for this year.
-
Targeting adjusted EBITDA breakeven by the end of 2026 and positive adjusted EBITDA in the second half of 2027 with a 60% incremental revenue reduction to the bottom line.
-
Assuming continued ASP growth as customers migrate to higher-value products such as MSK-ACCESS and Advanced Exomes, despite lower ASP volume growth in emerging markets.
-
Planning to maintain operating costs in local currency by providing regulatory structures and optimizing discretionary costs.
-
A significant negative foreign exchange impact was reported due to a 14% appreciation of the Swiss franc, which increased wage and rental costs in US dollar terms.
-
incurred $1.8 million in legal costs related to patent litigation with Guardian Health; However, the Unified Patent Court recently denied Guardant’s request for interim measures.
-
Strengthened liquidity by raising $15.5 million through ATM facilities and expanding credit facilities with significant advisors by $25 million.
-
Record low net dollar retention of 115%, up from 104% last year, driven by successful cross-selling of additional clinical applications.
